WHO recommends two new drugs for COVID-19 treatment
Year of ensuring human interests and development of the mahalla
Decrees of the President of the Republic of Uzbekistan
Investment potential of Uzbekistan
Meetings
The international cooperation
Millenium development goals
Press-releases
Mission News
The Strategy of Actions on Further Development
Independence Day of the Republic of Uzbekistan
Uzbekistan’s Candidacy to Human Rights Council
Tourism
December 8 - Constitution Day of the Republic of Uzbekistan
Press Digests of Uzbekistan
Constitutional reform
Other news and events
For consular and visa issues, please contact the Embassy of the Republic of Uzbekistan in Berlin:
Perleberger Str. 62, 10559 Berlin
Tel.: +49 30 394 098 30/80
Fax: +49 30 394 098 62
botschaft@uzbekistan.de
Hotline of the Ministry of Foreign
Affairs of Uzbekistan:
+998 71 233 28 28
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.
According to WHO, the first drug, baricitinib, is strongly recommended for patients with severe or critical COVID-19. It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system. WHO recommends that it is given with corticosteroids.
WHO has also conditionally recommended the use of a monoclonal antibody drug, sotrovimab, for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.
Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that sotrovimab retains its activity.
The two newly recommended drugs – baricitinib and sotrovimab – have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.
UzA
